MAUDE MDR 7013360

MDR report key
7013360
Report number
1823260-2017-02563
Event key
0
Event type
3
Date of event
2017-10-20
Date received
2017-11-09
Adverse event
3
Product problem
3
Patients in event
0
Reporter occupation
100
Health professional
3
Initial report to FDA
3
Event location
3

Manufacturer Contact#

Contact
NA MICHAEL LESLIE
Address
9115 HAGUE ROAD NA INDIANAPOLIS IN 46250 US
Phone
317-317-3175
Report source
M
Manufacturer link flag
Y

Devices#

Seq, Brand, Generic table
SeqBrandGenericManufacturerProduct codeModelCatalogLotPMA510(k)ImplantEvaluatedAvailability
1ELECSYS T4 ASSAYRADIOIMMUNOASSAY, TOTAL THYROXINEROCHE DIAGNOSTICSCDXNA12017709122248077R Y

Patients#

Sequence, Received, Treatment table
SequenceReceivedTreatmentOutcome
12017-11-090

Event Narratives#

N

Patient 1

THIS EVENT OCCURRED IN (B)(6). (B)(4).

D

Patient 1

THE CUSTOMER STATED THAT THEY RECEIVED AN ERRONEOUS RESULT FOR ONE PATIENT SAMPLE TESTED FOR THE ELECSYS T4 ASSAY (T4) ON A COBAS E 411 IMMUNOASSAY ANALYZER (E411). THE ERRONEOUS RESULT WAS NOT REPORTED OUTSIDE OF THE LABORATORY. THE SAMPLE RESULTED WITH A T4 VALUE OF 18 UG/ML WHEN TESTED ON THE CUSTOMER'S E411 ANALYZER. THE SAMPLE WAS TESTED ON A VIDAS ANALYZER AND THE T4 RESULT WAS 9 UG/ML. THE SAMPLE WAS ALSO TESTED ON A SECOND E411 ANALYZER IN A DIFFERENT LABORATORY, RESULTING WITH A T4 VALUE OF 20 UG/ML. A FRESH SAMPLE WAS COLLECTED FROM THE PATIENT AND TESTED. THE VALUES FROM THIS SAMPLE WERE THE SAME AS PREVIOUS VALUES. NO ADVERSE EVENTS WERE ALLEGED TO HAVE OCCURRED WITH THE PATIENT. THE SERIAL NUMBERS OF THE E411 ANALYZERS USED AT THE CUSTOMER SITE AND OTHER LABORATORY WERE ASKED FOR, BUT NOT PROVIDED. THE CUSTOMER DOES NOT USE QUALITY CONTROL MATERIAL. DURING TROUBLESHOOTING, QUALITY CONTROL MATERIAL WAS TESTED ON THE CUSTOMER'S E411 ANALYZER AND RECOVERED WITHIN LIMITS. CALIBRATION SIGNALS WERE WITHIN RANGE ON THE CUSTOMER'S E411 ANALYZER. NO ISSUES WERE FOUND WITH THE CUSTOMER'S E411 ANALYZER. CALIBRATION AND QUALITY CONTROL RECOVERIES AT THE OTHER LABORATORY WERE WITHIN LIMITS.